Edesa Biotech, Inc.
EDSA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $3 | $5 | $13 |
| G&A Expenses | $4 | $4 | $4 | $5 |
| SG&A Expenses | $4 | $4 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | -$1 |
| Operating Expenses | $8 | $7 | $9 | $18 |
| Operating Income | -$8 | -$7 | -$9 | -$18 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$7 | -$6 | -$8 | -$18 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$6 | -$8 | -$18 |
| % Margin | – | – | – | – |
| EPS | -1.27 | -1.93 | -2.93 | -8.37 |
| % Growth | 34.2% | 34.1% | 65% | – |
| EPS Diluted | -1.27 | -1.93 | -2.93 | -8.37 |
| Weighted Avg Shares Out | 6 | 3 | 3 | 2 |
| Weighted Avg Shares Out Dil | 6 | 3 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$6 | -$8 | -$17 |
| % Margin | – | – | – | – |